2. Patients who have received systematic antidepressant treatment (including antidepressant medications, sedative-hypnotics, electroconvulsive therapy, or transcranial magnetic stimulation) within the 4 weeks prior to enrollment;
3. Having a total score on the 17-item Hamilton Depression Rating Scale (HAMD-17) greater than 7 and less than or equal to 24;
4. Voluntary participation in the study, with written informed consent provided by the patient themselves or their legally authorized guardian.
You may not be if
1. Diagnosis of other major psychiatric disorders or presence of psychotic symptoms.
2. History of other severe somatic diseases (e.g., cardiovascular/cerebrovascular diseases, autoimmune diseases), or current/past neurological or organic brain diseases.
3. Current or past history of alcohol dependence or abuse of other psychoactive substances.
4. Women who are lactating, pregnant, or menstruating.
5. Patients who have participated in other clinical drug trials within the past 3 months.
Clareo Health | Multimodal MRI Study of Acupuncture's Rapid Antidepressant Mechanisms and Response Prediction in Depression
